Be the first person to write a business review for EXACT Sciences Corporation

Exalpha Biologicals supplies drug and medical device researchers with reagents, monoclonal and polyclonal antibodies, assay kits, and other biological products used in their R&D work. The company offers some 350 products. The company distributes its products internationally through a network of some 30 different partners. Exalpha Biologicals provides distribution services for the company in the US.

Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

Expression Analysis isn't run by body language specialists, but when researchers need DNA analyzed, they can turn to Expression Analysis. The company provides outsourced microarray processing, genotyping, RNA amplification and isolation, and other data generation and analysis services. The company uses gene research platforms developed by companies including Affymetrix, Life Technologies, and Illumina. It analyzes a variety of samples including whole blood, tissue cells, and frozen samples, for customers including government agencies and pharmaceutical development firms.

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California.

Ferring Pharmaceuticals is owned by Swiss drugmaker Ferring Group, which was founded in 1951 and expanded into the US in the early 1980s. Ferring Pharmaceuticals knows that birthing babies is hard work. The company develops and markets a variety of fertility products, including hormone treatments Bravelle, Menopur, Novarel, and Repronex. The company also develops and manufactures products to diagnose and treat ailments in the areas of urology, endocrinology, osteoarthritis, and gastroenterology, including Euflexxa for osteoarthritis of the knee, Prosed for lower urinary tract infections, and Acthrel, a diagnostic agent for Cushing's syndrome.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.